Avelumab Program Rollover Study (NCT03815643)

🧪 Interventions in This Study

• Avelumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (104 Sites)

Showing the first 25 of 104 sites.

• HonorHealth Research Institute — Scottsdale, Arizona
• Highlands Oncology Group — Fayetteville, Arkansas
• University of California Davis Health System - Comprehensive Cancer Center — Sacramento, California
• Providence Medical Foundation — Santa Rosa, California
• St Joseph Heritage Healthcare — Santa Rosa, California
• Norwalk Hospital - The Whittingham Cancer Center — Norwalk, Connecticut
• Hematology - Oncology Associates of the Treasure Coast - Hematology-Oncology Associates of Treasure Coast — Port Saint Lucie, Florida
• Northwest Georgia Oncology Centers — Marietta, Georgia
• Maryland Oncology Hematology, P.A. — Rockville, Maryland
• Michigan State University — Lansing, Michigan
• Virginia Piper Cancer Institute — Minneapolis, Minnesota
• Kansas City Research Institute, LLC - Phase I Unit — Kansas City, Missouri
• University of Cincinnati - PARENT — Cincinnati, Ohio
• Oncology Hematology Care — Cincinnati, Ohio
• Oncology/Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
• OSU - James Comprehensive Cancer Center — Columbus, Ohio
• Oregon Health & Science University — Portland, Oregon
• Rhode Island Hospital — Providence, Rhode Island
• Medical University of South Carolina (MUSC) — Charleston, South Carolina
• Greenville Hospital System University Medical Center (ITOR) - Upstate Affiliate Organization — Greenville, South Carolina
• The West Clinic — Germantown, Tennessee
• SCRI - Tennessee Oncology — Nashville, Tennessee
• University of Texas Southwestern Medical Center — Dallas, Texas
• Oncology Consultants, P.A. — Houston, Texas
• Henry Ford Hospital — San Antonio, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.